After more than 3 years of milestone-based support and coaching, the Swiss Innovation Agency conferred to us the Innosuisse Certificate, certifying that Lymphatica is ready for sustainable investment and sustainable growth.
Lymphatica’s CEO participated to both the live and live events of the Tech Tour Health 2021, and received the Award as Top Presenting Company In recognition for outstanding Pitching performance throughout the Program and high quality presentation as evaluated by a panel of International Investor Reviewers. The winner will be invited to pitch at the annual Tech Tour Event Future22 in March 2022.
More info at this link
After approval by Swissmedics and by the CER-VD Ethical committee, the LymphoPILOT clinical trial officially started.
For a more details about the study please visit clinical trial.gov
We are happy to announce that we have closed a 7 digit Series A financing round!
The investment round was led by the High Tech Gründerfonds (https://www.htgf.de/en/) , a large and experienced German VC fund that will accompany on our way forward.
New business angels joined the round, as well as the existing ones, who confirmed the trust in our team.
The EIT Health (https://eithealth.eu/ – European Institute of Technology) contributed to the financement, funding development activities to improve the usability and digitalization of our product, LymphoDRAIN.
Together with the cash, we welcome Laurent Duhoux as new member of our Board of Directors. With a proven track record in managing medical technology businesses, Laurent brings to Lymphatica his 20-year experience.
We’ll use the funds to advance in the roadmap to bring LymphoDRAIN to lymphedema patients.
More details in our press release
Notified body TÜV SÜD granted the ISO 13485 certification to Lymphatica Medtech SA!
ISO 13485 is the international quality management system standard for medical devices.
This certification confirms that Lymphatica operated through highly controlled quality proceses and procedures tailored to optimized the design & development of medical devices.
The certification was awarded following independent audits according to ISO 13485:2016 requirements.
The European Innovation Council of the European Union supports LymphoDrain implant market entry with €1.8 millions grant, via its H2020 SME Instrument program. This additional fund will accelerate the market entry process, supporting pre-series manufacturing and clinical trials.
Being awarded in such a highly competitive selection process is a recognition of excellence of the presented product innovation and of the expected large societal impact.
The EIC Accelerator (former SME Instrument) is a public funding program that funds breakthrough innovation in small businesses. Only the most innovative companies get selected: only 83 projects were funded out of 1765 submitted proposals at the April 2019 call.
Lymphatica is selected among the 10 Venture Leaders for a fundraising campaign in China
Lymphatica presents at the International Lymphoedema Framework Conference in Chicago
We will present our latest results at the International Lymphatic Framework Conference in Chicago (13-15 June, 2019). Please come and visit us!
Lymphatica Medtech was selected between the presenting companies at the 28th Medtech Investing Europe Conference
CHUV, our main clinical partner, is rated as one of "The 10 Best hospitals in the World" (NewsWeek)
Lymphatica participates to a round table to discuss about the future of lymphedema care